AdoraPet Biosciences

AdoraPet Biosciences

Early Stage

Invest in Pets that don't cause allergies

Invest in Pets that don't cause allergies


Raised this Round: Raised: $0

Total Commitments ($USD)


Dealmaker Securities

Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Pet Health, Food, and Services

Tech Sector


Distribution Model




Capital Intensity



San Mateo, California

Business Type


AdoraPet Biosciences, with a valuation of $20 million, is raising funds on DealMaker Securities. The company’s goal is to allow pets and owners to spend more time together by using state-of-the-art gene technology to eliminate the genes that cause allergies in owners and diseases in our pets. CRISPR is a Nobel Prize-winning technology scientists can use to remove problem-causing genes. AdoraPet plans to use CRISPR technology to modify these genes in embryos, creating allergy-free, long-living pets for everyone. Dr. Richard Chin, Dr. Stephen Sundlof and Dr. George Church founded AdoraPet in 2022. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5,000,000.

Summary Profit and Loss Statement

FY 2022 FY 2021












Net Income



Summary Balance Sheet

FY 2022 FY 2021




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 12/18/2022
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
AdoraPet Biosciences on DealMaker 2022
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $35,000,000
Price per Share: $5.00

Follow company

Follow AdoraPet Biosciences on DealMaker 2022

Buy AdoraPet Biosciences's Deal Report

Warning: according to the close date for this deal, AdoraPet Biosciences may no longer be accepting investments.

AdoraPet Biosciences Deal Report

Get KingsCrowd’s comprehensive report on AdoraPet Biosciences including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether AdoraPet Biosciences is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the AdoraPet Biosciences deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge